AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
Launched by MEDTRONIC - MITG · Nov 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The AFFIX clinical trial is studying a new device called the MaxTack™ Motorized Fixation Device, which is used during minimally invasive surgery to repair ventral hernias. A ventral hernia occurs when tissue bulges through a weak spot in the abdominal muscles. This study aims to see how well the device works and how safe it is when fixing a special type of mesh to the tissue during the surgery.
To participate in this trial, you need to be at least 18 years old and undergoing a planned surgery for a ventral hernia. You should not have had multiple hernia repairs before or have any infections at the time of surgery. Participants can expect to follow a specific schedule for check-ups after the surgery to ensure everything is healing properly. This study is open to all genders and is currently recruiting participants. If you or a loved one are considering ventral hernia surgery, this trial may offer an opportunity to help advance medical knowledge while receiving care with the new device.
Gender
ALL
Eligibility criteria
- Preoperative Inclusion Criteria:
- • 1. Subject has provided informed consent (IC)
- • 2. Subject is 18 years of age or older at the time of consent
- • 3. Subject is able and willing to comply with the study requirements and follow-up schedule
- • 4. Subject is undergoing an elective, single-stage, primary or incisional ventral hernia repair
- • 5. Subject is undergoing minimally invasive ventral hernia repair procedure using the MaxTack™ Motorized Fixation Device
- • 6. Subject is undergoing minimally invasive ventral hernia repair procedure using a Medtronic (including Covidien) mesh that is intended to be used in compliance with the mesh Instructions for Use (IFU)
- • 7. Subject is expected to meet the criteria for a class I wound (clean) as defined by Centers for Disease Control and Prevention (CDC) classification
- Preoperative Exclusion Criteria:
- • 1. Subject is undergoing an emergency surgery (e.g., lifesaving procedures performed where subject is in imminent danger of death, strangulated hernia, etc.)
- • 2. Subject has history of 3 or more hernia repair procedures
- • 3. Subject has existing mesh in the space where the physician needs to apply the new mesh to be fixated with the MaxTack™ Motorized Fixation Device
- • 4. Subject is scheduled (or anticipated to be scheduled) for additional surgery, and subsequent surgery would jeopardize previous application of study treatment
- • 5. Subject has history of allergic reactions to Poly (Glycolide-co-L-lActide) (PGLA)
- • 6. Subject has history of allergic reactions to the components of the intended mesh
- • 7. Subject has any systemic or local ongoing infection at the time of the surgery
- • 8. Subject has a Body Mass Index (BMI) greater than 45 kg/m2
- • 9. Subject has life expectancy in the opinion of the investigator, of less than 3 years at the time of enrollment
- • 10. Subject is pregnant (as determined by standard site practices) or is planning to become pregnant during study duration period.
- • 11. Subject has participated or will participate in an investigational drug or device research study that would interfere with the results of this study
- • 12. Subject's participation in the study may jeopardize the safety or welfare of the subject, as determined by the investigator
- • 13. Subject is already enrolled or was previously enrolled in this study
- Intraoperative Exclusion Criteria:
- • 1. Subject did not receive the MaxTack™ Motorized Fixation Device tacks to fixate the mesh
- • 2. Subject did not receive a Medtronic (including Covidien) mesh
- • 3. Inability to comply with the mesh IFU
- • 4. Subject required more than a single piece of mesh
- • 5. Subject has a surgical wound classified as Class II (clean-contaminated), Class III (contaminated) or Class IV (dirty/infected) as defined by the CDC classification
- • 6. Subject with an American Society of Anesthesiologists (ASA) score of Class 4, 5, or 6
- • 7. Inability to close the hernia defect
- • 8. Subject's procedure required a multi-stage repair
- • 9. Subject's minimally invasive procedure required to convert to open
About Medtronic Mitg
Medtronic - Minimally Invasive Therapies Group (MITG) is a leading global sponsor focused on advancing minimally invasive surgical techniques and technologies to improve patient outcomes and optimize healthcare delivery. Committed to innovation and excellence, MITG develops a range of products and solutions that enhance surgical precision and efficiency, catering to a diverse array of medical conditions. Through rigorous clinical trials and research initiatives, Medtronic MITG aims to drive evidence-based practices in healthcare, ensuring that patients benefit from the latest advancements in minimally invasive procedures.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Cleveland, Ohio, United States
Weston, Florida, United States
Patients applied
Trial Officials
Haresh Sachanandani
Study Director
Medtronic (Sponsor)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported